What Therabel Group does

Therabel Group is a privately-owned European pharmaceutical company founded in 1945, headquartered operationally in Forest (Brussels), Belgium. The company specializes in the commercialization of specialty care and primary care prescription pharmaceuticals (Rx) as well as over-the-counter (OTC) products, with key franchises spanning cardiology, pain management (covering the full WHO pain ladder), supportive oncology care, respiratory, urology, and gastroenterology, alongside an OTC portfolio in vitamins/minerals, cough and cold, and gastroenterology. Its core technology and product capability rests on a regulatory-licensed pharmaceutical portfolio — including branded assets such as Coruno BF and Corvaton Bf — developed internally and through decades of M&A (La Meuse 1986, Lucien Pharma 1991, Gienne Pharma 1997, Javelin Pharmaceuticals UK 2009), manufactured at the Therabel Industries production site in southern France and supplied globally through Therabel Pharmaceuticals Ltd in Ireland.

Therabel's business model is partnership-driven: rather than competing head-on with Big Pharma on discovery, it acts as a "one-stop shop" for companies seeking to commercialize products in Europe and selected emerging markets. Revenue is generated through licensing, royalties, distribution agreements, joint ventures, co-marketing, and co-promotion arrangements. The company maintains direct commercial presence in France, Belgium, and Luxembourg, and operates through commercialization partners across an additional 15 countries spanning Western Europe (Switzerland), Africa (13 markets), the Middle East (Lebanon), and Southeast Asia (Cambodia). It serves two primary end-customer layers: pharmaceutical companies seeking European market access (B2B) and, downstream, European physicians, pharmacists, hospital specialists, and patients at both hospital and retail/primary care levels. Pricing is not publicly disclosed and is contractually negotiated; group turnover was €59.1 million in 2019 per company-reported key facts, and the company has been privately held since founding with no parent company, external investors, or disclosed funding rounds.

Name

Therabel Group

Legal name

THERABEL INTERNATIONAL SERVICES SA/NV

Website

https://therabel.com

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

251–500 employees

Short description

Therabel Group is a privately-owned European pharmaceutical company founded in 1945 that commercializes specialty and primary care Rx and OTC products via a partnership-driven model, serving pharma licensors and downstream European physicians, pharmacists, and patients across 18 countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical products
• Prescription drugs
• OTC medicines
• Market access services
• Pharmaceutical partnerships

Headquarters

HQ city

Breda

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical product commercialization: Therabel generates revenue through partnerships with pharmaceutical companies, including in-licensing, out-licensing, distribution agreements, joint-ventures, co-marketing, and co-promotion arrangements. The business model focuses on providing regulatory support, market access, and sales & marketing activities for partnered products.

Go-to-market motion2 records

Distribution channels3 records

Core offering

Therabel Group develops, manufactures, and commercializes prescription (Rx) and OTC pharmaceutical products in Europe, covering cardiology, pain management, supportive oncology care, respiratory, urology, and gastroenterology, as well as OTC categories such as vitamins and minerals, cough and cold. The company operates as a partnership-driven commercialization platform, offering European market access services from regulatory registration through pricing, reimbursement, sales, and marketing to pharma partners.

Product overview

Therabel Group is a privately-owned European pharmaceutical company established in 1945, operating primarily as a partnership-driven organization that commercializes specialty care and primary care pharmaceutical products alongside OTC products. The company focuses on prescription key franchises in cardiology, pain management (covering the full WHO pain ladder), supportive oncology care, respiratory, urology, and gastroenterology. Its OTC portfolio spans vitamins and minerals, cough and cold, and gastroenterology categories. Products are distributed through direct commercial presence in France, Belgium, and Luxembourg, with commercialization partners serving other European and international markets. Notable branded products include Coruno BF and Corvaton Bf, with historical portfolio built through acquisitions of companies such as La Meuse (Belgium), Lucien Pharma (France), Gienne Pharma (Italy), and Javelin Pharmaceuticals UK Ltd. The business model emphasizes partnerships, in-licensing, out-licensing, distribution agreements, joint ventures, co-marketing, and co-promotion arrangements.

Differentiator

Problem solved

Functional benefit

Products and services

• Coruno BF Cardiovascular prescription medication marketed in Belgium for the treatment of angina pectoris and heart failure prevention.
• Corvaton Bf Cardiovascular prescription medication marketed in Belgium for pulmonary arterial hypertension and related cardiac conditions.
• Prescription key franchises Range of prescription pharmaceutical products across cardiology, pain management (covering the full WHO pain ladder), supportive oncology care, respiratory, urology, and gastroenterology franchises distributed through physicians and pharmacists across Europe.
• OTC key categories Over-the-counter pharmaceutical portfolio spanning vitamins and minerals, cough and cold, and gastroenterology categories sold through retail pharmacies across European and partner markets.
• European pharmaceutical partnership and market access services One-stop-shop partnership offering for pharmaceutical companies seeking to commercialize products in Europe, providing capabilities from regulatory registration to pricing, reimbursement, and sales & marketing through European-wide product licenses, distribution agreements, joint ventures, co-marketing, and co-promotion arrangements.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Pharmaceutical Partners (unspecified)coreStrategic or Co-development PartnerTherabel's business model is fundamentally built on partnerships with other pharmaceutical companies. They collaborate on new, close-to-market or marketed products in major European countries. Partnership types include European-wide product licenses, distribution agreements, Joint-Ventures, co-marketing agreements, and co-promotion agreements. The company focuses on bringing safe and effective therapeutic solutions developed by partners to European healthcare professionals and patients.

Scale indicators3 records

Recent moves11 records

Expansion highlights4 records

Direct peers

• Almirall S.A. Spanish-based European specialty pharma focused on dermatology and other specialty areas; comparable in mid-cap size, European geographic focus and reliance on in-licensed and proprietary specialty products.
• Pierre Fabre Group: Privately-held French pharmaceutical and dermo-cosmetics group with both Rx and OTC offerings across European markets — comparable partnership-driven model and direct commercial presence in France and Benelux.
• Stada Arzneimittel AG: Privately-owned European specialty and generics pharma with broad therapeutic portfolio and strong distribution across European retail and hospital channels — directly comparable to Therabel's mix of Rx franchises plus OTC and pan-European commercial reach.
• Laboratoires Servier: Independent French-headquartered pharma group with cardiovascular, oncology and other specialty franchises and significant European commercial reach — closely comparable given privately-held status and French/Benelux commercial anchor.
• Gedeon Richter Plc. Hungarian-headquartered European specialty/generics pharma with cardiology, women's health and CNS franchises — comparable mid-cap European footprint and own-manufacturing plus licensing business model.
• Faes Farma S.A. Spanish specialty pharma with OTC and Rx portfolios across respiratory, gastroenterology and dermatology — comparable scale, therapeutic spread, and Southern-European anchor with European distribution ambitions.
• Neuraxpharm Group: Privately-held European specialty pharma focused on CNS, with a pan-European footprint built via licensing and bolt-on acquisitions — highly comparable partnership-driven European commercialization model.
• Recordati S.p.A. Italian-headquartered European specialty pharma with established presence in cardiology, urology and pain — overlapping therapeutic franchises and a similar model of in-licensing and own-brand commercialization across multiple European markets.
• Mundipharma: Privately-held network of associated pharma companies with European and emerging-market presence spanning pain, oncology and respiratory — comparable private ownership structure and multi-geography partnership-driven model.

Broad incumbents

• Ipsen: French-listed specialty pharma with European roots and growing focus on oncology, neurology and rare disease — broader and larger than Therabel but overlapping in European specialty distribution and partnership-led portfolio expansion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therabel Group